CCR2 INHIBITOR CCX140 EFFECTIVE IN PHASE 2 CLINICAL TRIAL IN DIABETIC NEPHROPATHY

被引：0

作者：

de Zeeuw, Dick ^{[1
]}

Henkel, Elena ^{[2
]}

Psottova, Jana ^{[3
]}

Paragh, Gyorgy ^{[4
]}

Mehling, Heidrun ^{[5
]}

Hasslacher, Christopher ^{[6
]}

Potarca, Antonia ^{[7
]}

Bekker, Pirow ^{[8
]}

Schall, Thomas J. ^{[9
]}

机构：

[1] Univ Med Ctr Groningen, Clin Pharm & Pharmacol, NL-9713 AV Groningen, Netherlands

[2] Tech Univ Dresden, Diabet, D-01062 Dresden, Germany

[3] Diainmed, Diabet, Prague, Czech Republic

[4] Univ Debrecen, Diabet, Debrecen, Hungary

[5] Free Univ Berlin, Diabet, Berlin, Germany

[6] Heidelberg Univ, Diabet, Heidelberg, Germany

[7] ChemoCentryx, Clin Operat, Mountain View, CA USA

[8] ChemoCentryx, Med & Clin Affairs, Mountain View, CA USA

[9] ChemoCentryx, R&D, Mountain View, CA USA

来源：

NEPHROLOGY DIALYSIS TRANSPLANTATION | 2015年 / 30卷

关键词：

D O I：

10.1093/ndt/gfv195.1

中图分类号：

R3 [基础医学]; R4 [临床医学];

学科分类号：

1001 ; 1002 ; 100602 ;

摘要：

SP457

引用

页数：1

共 50 条

[21] Loganin alleviates macrophage infiltration and activation by inhibiting the MCP-1/CCR2 axis in diabetic nephropathy
Du, Qiu
Fu, Ying-xue
Shu, An-mei
Lv, Xing
Chen, Yu-ping
Gao, Yu-yan
Chen, Jing
Wang, Wei
Lv, Gao-hong
Lu, Jin-fu
Xu, Hui-qin
LIFE SCIENCES, 2021, 272
[22] Role of MCP-1/CCR2 in diabetic glomerulosclerosis
Kanamori, Hiroshi
Matsubara, Takeshi
Mima, Akira
Sumi, Eriko
Iehara, Noriyuki
Fukatsu, Atsushi
Doi, Toshio
Kita, Toru
Arai, Hidenori
DIABETES, 2006, 55 : A180 - A180
[23] Chemokine receptor 2 antagonist CCX140-B in Phase 2 for type 2 diabetes
Sullivan, T.
Miao, S.
Berahovich, R.
Zhao, N.
Ungashe, S.
Johnson, D.
Bekker, P.
Jean, J.
Schall, T. J.
DIABETOLOGIA, 2010, 53
[24] Effects of a CCR2 antagonist on macrophages and Toll-like receptor 9 expression in a mouse model of diabetic nephropathy
Ito, Seigo
Nakashima, Hiroyuki
Ishikiriyama, Takuya
Nakashima, Masahiro
Yamagata, Akira
Imakiire, Toshihiko
Kinoshita, Manabu
Seki, Shuhji
Kumagai, Hiroo
Oshima, Naoki
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 2021, 321 (06) : F757 - F770
[25] Evaluation of a novel chemokine receptor 2 (CCR2)-antagonist in painful diabetic polyneuropathy
Kalliomaki, Jarkko
Jonzon, Bror
Huizar, Karin
O'Malley, Michael
Andersson, Anita
Simpson, David M.
SCANDINAVIAN JOURNAL OF PAIN, 2013, 4 (02) : 77 - 83
[26] Role of CCR2 in the Development of Streptozotocin-Treated Diabetic Cardiomyopathy
Tan, Xin
Hu, Lizhi
Shu, Zhiping
Chen, Long
Li, Xiangrao
Du, Meng
Sun, Dan
Mao, Xiaoxiang
Deng, Shan
Huang, Kai
Zhang, Fengxiao
DIABETES, 2019, 68 (11) : 2063 - 2073
[27] A CCR2/5 Inhibitor, PF-04634817, Is Inferior to Monthly Ranibizumab in the Treatment of Diabetic Macular Edema
Gale, Jeremy D.
Berger, Brian
Gilbert, Steven
Popa, Serghei
Sultan, Marla B.
Schachar, Ronald A.
Girgenti, Douglas
Perros-Huguet, Christelle
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2018, 59 (06) : 2659 - 2669
[28] Inhibition of CCR2 potentiates the checkpoint inhibitor immunotherapy in pancreatic cancer
Jung, Heiyoun
Ertl, Linda
Janson, Christine
Schall, Thomas
Charo, Israel
CANCER IMMUNOLOGY RESEARCH, 2016, 4 (11)
[29] ALLOSTERIC C-C CHEMOKINE RECEPTOR TYPE 2 (CCR2) INHIBITION IMPROVES RENAL FUNCTION IN A MURINE MODEL OF DIABETIC NEPHROPATHY
Miao, Zhenhua
Ertl, Linda S.
Zhao, Bin
Wang, Yu
Newland, Dale
Zeng, Yibin
McMahon, Jeffrey
Liu, Xiaoli
Dang, Ton
Miao, Shichang
Zhang, Penglie
Li, Chris
Campbell, James
Singh, Rajinder
Charo, Israel F.
Schall, Thomas J.
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2020, 35 : 1296 - 1296
[30] Effect of PF-04634817, an Oral CCR2/5 Chemokine Receptor Antagonist, on Albuminuria in Adults with Overt Diabetic Nephropathy
Gale, Jeremy D.
Gilbert, Steven
Blumenthal, Samuel
Elliott, Tom
Pergola, Pablo E.
Goteti, Kosalaram
Scheele, Wim
Perros-Huguet, Christelle
KIDNEY INTERNATIONAL REPORTS, 2018, 3 (06): : 1316 - 1327

← 1 2 3 4 5 →